O- Or S- Glycosides Patents (Class 536/4.1)
  • Patent number: 9121060
    Abstract: The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3?-OH blocking group covalently attached thereto, such that the 3? carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R?)2-O—R?, —C(R?)2-N(R?)2, —C(R?)2-N(H)R?, —C(R?)2-S—R? and —C(R?)2-F, wherein each R? is or is part of a removable protecting group; each R? is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R?)2 represents an alkylidene group of formula ?C(R??)2 wherein each R?? may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R? is exchanged for H or, where Z is —C(R?)2-F, the F is ex
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: September 1, 2015
    Assignee: Illumina Cambridge Limited
    Inventors: John Milton, Xiaolin Wu, Mark Smith, Joseph Brennan, Colin Barnes, Xiaohai Liu, Silke Ruediger
  • Patent number: 9101162
    Abstract: The present invention provides a process for preparation of highly purified mogrosides mixture from low purity mogrosides mixture.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: August 11, 2015
    Assignee: PureCircle Sdn Bhd
    Inventor: Avetik Markosyan
  • Patent number: 9045507
    Abstract: The design, synthesis, and utilization of a novel coumarin-based amino acid and its fluorinated derivatives for use in enzyme activity and substrate specificity assays are described. The synthesis is both facile and high-yielding and allows for the production of a highly fluorescent phosphorylated amino acid that can be incorporated into peptides using standard SPPS techniques. The resultant substrates are efficiently hydrolyzed by PTPs and exhibit a large increase in fluorescence upon hydrolysis. Fluorinated CAP derivatives have utility as fluorogenic enzyme substrates. CAP and its derivatives can be incorporated into combinatorial peptide libraries for assaying enzyme substrate specificities.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: June 2, 2015
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Amy M. Barrios, Sayantan Mitra
  • Publication number: 20150140610
    Abstract: A process for making the compound of Formula I utilizes the starting compound, together with sulfilimine and sulfoxide process steps later on.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 21, 2015
    Inventors: Adrian Ortiz, Tamas Benkovics, Zhongping Shi, Prashant P. Deshpande, Zhiwei Guo, David R. Kronenthal, Chris Sfouggatakis
  • Publication number: 20150140576
    Abstract: The present invention describes glycans, which are specifically expressed by certain cancer cells, tumours and other malignant tissues. The present invention describes methods to detect cancer specific glycans as well as methods for the production of reagents binding to said glycans. The invention is also directed to the use of said glycans and reagents binding to them for the diagnostics of cancer and malignancies. Furthermore, the invention is directed to the use of said glycans and reagents binding to them for the treatment of cancer and malignancies. Moreover, the present invention comprises efficient methods to differentiate between malignant and benign tumors by analyzing glycan structures.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Applicant: GLYKOS FINLAND OY
    Inventors: Tero SATOMAA, Jari NATUNEN, Annamari HEISKANEN, Anne OLONEN, Juhani SAARINEN, Noora SALOVUORI, Jari HELIN
  • Patent number: 9034834
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: May 19, 2015
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Publication number: 20150133647
    Abstract: The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Applicant: Glycom A/S
    Inventors: Pauline Peltier-Pain, Gyula Dekany, Rémy Dureau, Christian Risinger, Markus Hederos, Elise Champion
  • Patent number: 9012413
    Abstract: The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R1 is an O-alkyl group optionally replaced by one or more aryl or cycloalkyl groups, R2 is an OSO3? or hydroxyl group, R3 is an alkyl, cycloalkyl, or alkyl-cycloalkyl group, R4 is a disaccharide having Formula (II), R6 is a disaccharide having Formula (III), and R8 is a disaccharide having Formula (IV), where R5, R7, and R9 are OSO3? or hydroxyl groups. The invention further relates to the preparation of said octasaccharides and to the therapeutic use thereof.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: April 21, 2015
    Assignee: Sanofi
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Pierre Fons, Corentin Herbert, Gilbert Lassalle
  • Patent number: 8993737
    Abstract: In various embodiments, the present invention provides fluorescent dyes that are linked to another species through an amino acid or peptide linker. In an exemplary embodiment, the dye is linked to a polyphosphate nucleic acid through an amino acid or peptide linker. These conjugates find use in single molecule DNA sequencing and other applications. In various embodiments, the dye moiety is a cyanine dye. Cyanine dyes that are highly charged, such as those including multiple sulfonate, alkylsulfonate, carboxylate and/or alkylcarboxylate moieties are examples of cyanine dyes of use in the compounds of the invention.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: March 31, 2015
    Assignee: Pacific Biosciences, Inc.
    Inventor: Gene Shen
  • Patent number: 8993740
    Abstract: The present invention relates to a method for preparation of the tetrasaccharide lacto-N-neotetraose (LNnt, formula (I)) especially in large scale, as well as intermediates in the synthesis, a new crystal form (polymorph) of LNnt, and the use thereof in pharmaceutical or nutritional compositions.
    Type: Grant
    Filed: February 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Glycom A/S
    Inventors: István Bajza, Gyula Dekany, Károly Ágoston, Ignacio Figuero-Pérez, Julien Boutet, Markus Hederos, Ferenc Horváth, Piroska Kovács-Pénzes, Lars Kröger, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas, Péter Trinka, László Kalmár, Irme Kovács, Sándor Demkó, Ágnes Ágoston, Christian Risinger
  • Patent number: 8993738
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 31, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 8987216
    Abstract: The invention relates to polysulfated glycosides of formula (I), the pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions containing these compounds as active ingredients. Furthermore the invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: March 24, 2015
    Assignees: Teva Hungary Pharmaceutical Marketing Private Limited Company, Teva Hungary Ltd.
    Inventors: János Kuszmann, István Kurucz, Gábor Medgyes, Nicholas Bodor
  • Patent number: 8980558
    Abstract: The present invention provides compositions, methods and kits for use in the detection of small RNA sequences, which allow for rapid and robust amplification and detection. The methods provide improved sensitivity and efficiency in the amplification-based detection of small RNA sequences by incorporating one or more base-modified duplex-stabilizing dNTPs during reverse transcription and/or amplification.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: March 17, 2015
    Inventor: Igor Vassily Kutyavin
  • Patent number: 8969535
    Abstract: Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3?-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group.
    Type: Grant
    Filed: August 23, 2012
    Date of Patent: March 3, 2015
    Assignee: Lasergen, Inc.
    Inventors: Weidong Wu, Vladislav A. Litosh, Brian P. Stupi, Michael L. Metzker
  • Patent number: 8962573
    Abstract: The invention relates to conjugates of products of interest including glycoproteins, nanoparticles, and imaging agents and of compounds of the general formula (1): that target the cation-independent mannose 6-phosphate receptor with a high affinity. The invention also relates to their applications, for instance in enzyme replacement therapies.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: February 24, 2015
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique—CNRS, Universite de Montpellier 1, Universite de Montpellier 2 Sciences et Techniques
    Inventors: Marcel Garcia, Alain Morere, Magali Gary-Bobo, Martine Cerutti, Khaled El Cheikh, Ilaria Basile, Philippe Nirde
  • Patent number: 8962578
    Abstract: The invention relates to novel fungicidally active compound combinations of 2?-cyano-3,4-dichloroisothiazole-5-carboxanilide and active compounds listed in the disclosure.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 24, 2015
    Assignee: Bayer CropScience AG
    Inventors: Peter Dahmen, Ulrike Wachendorff-Neumann, Rolf Pontzen, Lutz Assmann, Haruko Sawada
  • Publication number: 20150031630
    Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
    Type: Application
    Filed: May 17, 2012
    Publication date: January 29, 2015
    Inventor: John J. Nestor
  • Patent number: 8940879
    Abstract: To provide a functional molecule including a modified nucleotide unit having a substituent introduced to a base thereof, wherein the substituent is removably introduced to the base; a functional molecule synthesizing amidite that has a substituent removably introduced to its base and that is used for the manufacture of the functional molecule; and a target substance analysis method including: preparing a random pool of functional molecules using a functional molecule synthesizing amidite; screening a functional molecule having affinity for a target substance from the random pool; amplifying the functional molecules having affinity for the target substance, wherein the method further comprises, prior to the amplification step, removing a substituent from the functional molecule having affinity for the target substance.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: January 27, 2015
    Assignee: Apta Biosciences Ltd.
    Inventors: Tsuyoshi Fujihara, Shozo Fujita
  • Publication number: 20150025026
    Abstract: Campylobacter are the commonest reported bacterial causes of gastroenteritis in the UK and industrialized worlds. This invention relates to a method of preventing or reducing the colonisation of the gastrointestinal tract of an animal with Campylobacter. Accordingly, the present invention provides a method for disinfection of an animal comprising administering to said animal at least one compound that binds to MOMP or FlaA of Campylobacter in an effective amount to reduce the number of Campylobacter present in the gastrointestinal tract of said animal. The present invention also provides a method of preventing or reducing transmission of Campylobacter from one animal to another.
    Type: Application
    Filed: February 15, 2013
    Publication date: January 22, 2015
    Inventors: Jafar Mahdavi, Dlawer Ala'Aldeen
  • Publication number: 20150025030
    Abstract: A hydroxysafflor yellow A sodium compound as shown in a formula (I) and preparation as well as medicinal application thereof are provided. According to the present invention, the safflower is utilized as a raw material. A monomer pharmaceutical compound, the hydroxysafflor yellow A sodium, is obtained by sufficient processes, and a purity thereof is surely above 98.5%. Therefore, the hydroxysafflor yellow A sodium is a monomer compound, which is safer, more effective, more stable and more controllable than hydroxysafflor yellow A, for treating blood circulation disorders such as platelet aggregation, coronary heart disease, angina pectoris and acute cerebral ischemia. Furthermore, the hydroxysafflor yellow A sodium has sufficient solubility and human tolerance.
    Type: Application
    Filed: June 8, 2013
    Publication date: January 22, 2015
    Applicant: ZHEJIANG YONGNING PHARMACEUTICAL CO LTD
    Inventors: Fengqi Ye, Ben Cai, Min Lu, Yongling Chen
  • Patent number: 8937167
    Abstract: The present invention encompasses compounds and methods for treating urinary tract infections.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: January 20, 2015
    Assignee: Washington University
    Inventors: James W. Janetka, Zhenfu Han, Scott Hultgren, Jerome S. Pinkner, Corinne Cusumano
  • Patent number: 8927698
    Abstract: The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: January 6, 2015
    Assignee: Glycom A/S
    Inventors: Gyula Dékany, Istvan Bajza, Julien Boutet, Ignacio Pérez Figueroa, Markus Hederos, Ferenc Horvath, Piroska Kovács-Pénzes, Lars Kröger, Johan Olsson, Christoph Röhrig, Andreas Schroven, Ioannis Vrasidas
  • Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Patent number: 8927506
    Abstract: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: January 6, 2015
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Publication number: 20150004110
    Abstract: The 1-aryl-2-aryloxyethane compounds of Formula 1 in which n and m are zero or equal to 1, provided that n+m=1, R1 and R2 in particular representing hydrogen atoms, R3 and R4 in particular representing hydrogen atoms, halogen atoms, hydroxy or alkoxy groups, and R5 in particular representing hydrogen atoms, hydroxy, alkyl, alkoxy, amino or nitro groups, in cosmetic compositions intended for anti-ageing and/or depigmenting and/or anti-inflammatory and/or wound-healing care.
    Type: Application
    Filed: December 18, 2012
    Publication date: January 1, 2015
    Applicant: DIVERCHIM
    Inventors: Natacha Frison, Benoit Folleas, Jean-Louis Brayer, Florence Wafflart
  • Patent number: 8921532
    Abstract: The present invention provides labeled phospholink, nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays, and others.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: December 30, 2014
    Assignee: Pacific Biosciences of California, Inc.
    Inventor: Jonas Korlach
  • Publication number: 20140370549
    Abstract: The disclosure provides a method of producing a scyllo-inositol or a new scyllo-inositol derivative in a one-step process, from ubiquitous and inexpensive raw materials. Also provided is a scyllo-inositol derivative bonded to saccharides such as glucose and similar.
    Type: Application
    Filed: January 22, 2013
    Publication date: December 18, 2014
    Applicant: ASAHI KASEI CHEMICALS CORPORATION
    Inventors: Kazunobu Konishi, Shinichi Imazu
  • Publication number: 20140370501
    Abstract: The present invention provides novel methods for determining the presence or amount of a hydrolytic enzyme in a sample, based on novel substrates for the enzymes, and also provides compositions and methods that provide highly sensitive assay methods for such hydrolytic enzymes.
    Type: Application
    Filed: June 19, 2014
    Publication date: December 18, 2014
    Inventors: Chong-Sheng YUAN, Xiaoru CHEN
  • Patent number: 8912165
    Abstract: A method of treating an ulcer comprising applying to the ulcer a preparation comprising a water-soluble ?-(1,3) glucan with ?-(1,6) linked side-chains, where the side-chains comprise ?-(1,3) linkages or up to four consecutive ?-(1,6) linkages a active ingredients.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: December 16, 2014
    Assignee: Biotec Pharmacon ASA
    Inventors: Rolf Engstad, Rolf Seljelid
  • Patent number: 8907070
    Abstract: Glycolipids of branched chain alkyl oligosaccharides include a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either ?- or ?-linkage (shown in Formula I and Formula II). These compounds show phase behavior not found for the corresponding straight chain counterparts. The properties involve an ambient temperature liquid crystalline appearance and thermotropic liquid crystal phase polymorphism. The formation of cubic phases is considered most interesting with respect to life science applications, e.g. liposomes for drug delivery. Depending on the choice of sugar head group and alkyl tail, various levels of water miscibility may be adjusted to meet applications requirements (complete solubility for emulsifier applications, e.g. cosmetic creams, to limited water swelling only, e.g. for the preparation of artificial membranes).
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: December 9, 2014
    Assignee: Universiti Malaya
    Inventors: Rauzah Hashim, Thorsten Heidelberg, Hind Hassan, Nasrul Zamani Mohd Rodzi, Rusnah Syahila Dauli Hussen, Ahmad Sazali Hamzah, Shahidan Radiman, Volkmar Vill, Matthias Wulf, Seiji Ujiie
  • Patent number: 8889650
    Abstract: An antimelancholic pharmaceutical composition or health products prepared with jujuba cAMP materials and a preparative method are provided in the present invention. The present pharmaceutical composition includes jujuba cAMP as a solo effective ingredient for treating the depression. The present method for preparing the jujuba cAMP includes chromatographing a jujuba extract with a macroporous resin bound with an aldehyde group.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: November 18, 2014
    Assignees: Beijing Wonner Biotech, Ltd. Co.
    Inventor: Zuoguang Zhang
  • Publication number: 20140336136
    Abstract: The present invention relates to the use of certain stilbene derivatives for cosmetic and dermatological applications, in particular prevention and/or treatment of skin aging, as well as to cosmetic and dermatological compositions containing such stilbene derivatives.
    Type: Application
    Filed: May 7, 2014
    Publication date: November 13, 2014
    Applicant: RAHN AG
    Inventors: Jens Bitzer, Thomas Küper, Philipp Wabnitz
  • Patent number: 8883746
    Abstract: Disclosed are novel ?-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of ?-GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather than IFN-?and thus can be used as a therapeutic for autoimmune diseases regulated by IL-4, such as type 1 diabetes and multiple sclerosis.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: November 11, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Chang-Yuil Kang, SangHee Kim, Hyun-Jun Youn, Yoon-Sook Lee, Kyoo-A Lee, Taeho Lee, Dong Jae Baek, Minjae Cho
  • Patent number: 8877906
    Abstract: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: November 4, 2014
    Assignees: Wisconsin Aumni Research Foundation, UChicago Argonne, LLC
    Inventors: Samuel Helmer Gellman, Pil Seok Chae, Phillip D. Laible, Marc J. Wander
  • Patent number: 8877905
    Abstract: The present invention relates generally to labeled and unlabeled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: November 4, 2014
    Assignee: LaserGen, Inc.
    Inventors: Vladislav A. Litosh, Megan N. Hersh, Brian P. Stupi, Weidong Wu, Michael L. Metzker
  • Publication number: 20140315836
    Abstract: An object of the present invention is to provide a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder having an excellent suppressive effect on a keratoconjunctival disorder. The invention relates to a protective agent for the keratoconjunctiva or a suppressive agent for a keratoconjunctival disorder containing glucosylglycerol as an active ingredient, use of glucosylglycerol for the manufacture of a pharmaceutical for protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder and a method of protecting a keratoconjunctiva or suppressing a keratoconjunctival disorder comprising administering glucosylglycerol.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 23, 2014
    Inventors: Kyo Aizawa, Yoshihisa Iida, Takashi Shimoida, Yasuhiro Kotani, Koushi Iwaia, Kazuhisa Doi
  • Publication number: 20140315850
    Abstract: The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2?,3?-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2?,3?-Dideoxy-2,-a-fluoro-2?-{3-C-methyl-nucleosides can be considered as one unique class of 2?,3?-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2?-fluorine-a mimics 2?-a-OH group.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 23, 2014
    Applicant: Nanjing Molecular Research, Inc.
    Inventors: Qiang Huang, Suping Zhou, Junbiao Chang
  • Patent number: 8853372
    Abstract: A novel saccharide siloxane copolymer has improved stability in the presence of water as compared to certain previously known saccharide siloxanes. The saccharide siloxane copolymer is useful in personal care compositions.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: October 7, 2014
    Assignee: Dow Corning Corporation
    Inventors: James Anderson Beck, Lylenette Canfield, Michael Salvatore Ferritto, Eric Jude Joffre, Mark Keinath, Feifei Lin, Anil Kumar Tomar
  • Patent number: 8853373
    Abstract: Provided is a nucleic acid substrate which has nucleic acid substrate characteristics equivalent to those of dATP, has a low substrate specificity for luciferase, exerts no negative effect on enzymatic reactions such as a complementary-strand synthesis, and therefore is particularly suitable for the pyrosequencing method. As a nucleic acid substrate complementary to nucleotide T, a 7-substituted deoxyribonucleotide triphosphate whose 7-position of a purine group is modified by a substituent is used as a substitute for a nucleotide ?-thiotriphosphate analog.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: October 7, 2014
    Assignees: Hitachi, Ltd., National University Corporation Gunma University
    Inventors: Masayasu Kuwahara, Tomoharu Kajiyama, Hideki Kambara
  • Publication number: 20140296497
    Abstract: [Problem] To impart significantly improved myo-inositol producing capability, suitable for use in recombinant DNA techniques and synthetic biology methods, to a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway, such as Escherichia coli. [Solution] Inositol monophosphatase activity is strengthened in a transformant obtained by introducing a myo-inositol biosynthesis pathway into a host microorganism that does not possess an endogenous myo-inositol biosynthesis pathway.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 2, 2014
    Inventors: Kazunobu Konishi, Shinichi Imazu, Mayumi Sato
  • Patent number: 8846851
    Abstract: A salt catalyst comprises an ionic complex of i) a nitrogen base comprising one or more guanidine and/or amidine functional groups, and ii) an oxoacid comprising one or more active acid groups, the active acid groups independently comprising a carbonyl group (C?O), sulfoxide group (S?O), and/or a phosphonyl group (P?O) bonded to one or more active hydroxy groups; wherein a ratio of moles of the active hydroxy groups to moles of the guanidine and/or amidine functional groups is greater than 0 and less than 2.0. The salt catalysts are capable of catalyzing ring opening polymerization of cyclic carbonyl compounds.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: September 30, 2014
    Assignee: International Business Machines Corporation
    Inventors: Daniel J. Coady, Kazuki Fukushima, James L. Hedrick, Hans W. Horn, Julia E. Rice
  • Patent number: 8846881
    Abstract: Nucleic acid compositions, methods of making and using such compositions that comprise modular functional groups that can be configured to provide desired functionality to different nucleotide types, through a swappable and preferably non-covalent linkage component. Such compositions are useful in a variety of applications including nucleic acid analyses.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 30, 2014
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Jonas Korlach, Jeffrey Wegener
  • Publication number: 20140271474
    Abstract: Radiolabeled tracers for binding to sodium/glucose cotransporters (SGLTs), and their synthesis, are provided. The tracers are high-affinity inhibitors of SGLTs, glycosides labeled with radioactive halogens. Also provided are in vivo and in vitro techniques for using the tracers as analytical tools to study the biodistribution and regulation of SGLTs in health and disease, and to evaluate therapeutic interventions. The ability to monitor radiolabel tracer disposition in real time enables the design of new SGLT inhibitors with lower metabolism and higher efficiency.
    Type: Application
    Filed: June 14, 2012
    Publication date: September 18, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ernest M. Wright, Jorge R. Barrio
  • Publication number: 20140274930
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Evelyne Dietrich, Carl Poisson, Michel Gallant, Stephanie Lessard, Bingcan Liu, Sanjoy Kumar Das, Yeeman Ramtohul, Thumkunta Jagadeeswar Reddy, Julien Martel, Frederic Vallee, Jean-Francois Lévesque
  • Publication number: 20140275506
    Abstract: An alkenyl glycoside is prepared by reacting a metathesis-derived unsaturated fatty alcohol containing 10 to 30 carbon atoms with either (1) a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide, or (2) a hydrocarbyl glycoside produced by reacting an alcohol containing up to 6 carbon atoms with a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide. Each of these reactions is performed in the presence of an acid catalyst and under conditions sufficient to form the alkenyl glycoside or hydrocarbyl glycoside. The preferred alkenyl glycosides are 9-decen-1-yl glycoside; 9-dodecen-1-yl glycoside; 9-tridecen-1-yl glycoside; 9-pentadecen-1-yl glycoside; 9-octadecen-yl glycoside; or 9-octadecen-1,18-diyl glycoside.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: ELEVANCE RENEWABLE SCIENCES, INC.
    Inventors: Ryan A. Littich, Jonathan Brekan, Timothy Montavon
  • Publication number: 20140256924
    Abstract: Carbohydrates are biomolecules that are involved in a range of biological processes and play key roles in, for instance, host immune response and cellular adhesion. Accordingly, functionalisation of medical devices such as stents, valves, catheters, prostheses and other devices for in vivoimplantation with carbohydrates is an area in which considerable interest is developing. Disclosed herein are surfaces having carbohydrates immobilised thereon. The carbohydrate has a linker moiety covalently bound thereto and the linker moiety has a carbon atom that forms a covalent bond with an atom on the target surface. The carbon based bond is a strong, non-hydrolysable covalent bond.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 11, 2014
    Applicant: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF
    Inventors: Eoin M. Scanlan, Paula E. Colavita, Deirdre Murphy, Jean Bourke
  • Patent number: 8828952
    Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: September 9, 2014
    Assignee: Progen Pharmaceuticals Limited
    Inventors: Vito Ferro, Tomislav Karoli, Ligong Liu, Paul Newton Handley, Kenneth David Johnstone, Norbert Wimmer, Edward Timothy Hammond
  • Patent number: 8828955
    Abstract: The invention aims at finding a highly-safe natural product having glutathione production-enhancing activity, and providing a glutathione production enhancer and a prophylactic/therapeutic agent for diseases caused by glutathione deficiency using that natural product as an active ingredient. The glutathione production enhancer or the prophylactic/therapeutic agent for diseases caused by glutathione deficiency contains, as an active ingredient, a licorice extract composition that contains liquiritin, liquiritigenin, isoliquiritin and isoliquiritigenin but contains substantially no glycyrrhizic acid.
    Type: Grant
    Filed: May 1, 2009
    Date of Patent: September 9, 2014
    Assignee: Maruzen Pharmaceuticals Co., Ltd.
    Inventors: Nobuaki Ohto, Toshiyuki Murakami, Hirokazu Ohno
  • Publication number: 20140245496
    Abstract: Recombinant microorganisms, plants, and plant cells are disclosed that have been engineered to express a mutant AROM polypeptide and/or mutant catechol-O-methyltransferase polypeptide alone or in combination with one or more vanillin biosynthetic enzymes or UDP-glycosyltransferases (UGTs). Such microorganisms, plants, or plant cells can produce vanillin or vanillin beta-D-glucoside.
    Type: Application
    Filed: August 7, 2012
    Publication date: August 28, 2014
    Applicants: EVOLVA SA, INTERNATIONAL FLAVORS & FRAGRANCES INC.
    Inventors: Joergen Hansen, Esben Halkjaer Hansen, Honey Polur, Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton
  • Publication number: 20140234876
    Abstract: The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The present invention further provides a kit and method for detecting and quantifying the natural high intensity sweetener in a sample.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 21, 2014
    Applicant: PURECIRCLE SDN BHD
    Inventors: Jose Antonio Gabaldon Hernandez, Estrella Nunez Delicado, Rosa Puchades Pla, Angel Maquiera, Eva Maria Brun Sanchez, Avetik Markosyan